B3GNT2 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 1.79320003290684E-09 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
1.91103999999109E-05 |
Normal-vs-Stage2 |
2.009800E-04 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
1.233700E-02 |
Stage1-vs-Stage2 |
5.456100E-02 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
4.729000E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
4.546400E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
2.05769999928052E-08 |
Normal-vs-AfricanAmerican |
2.243800E-01 |
Normal-vs-Asian |
8.782100E-02 |
Caucasian-vs-AfricanAmerican |
6.657800E-03 |
Caucasian-vs-Asian |
6.906200E-01 |
AfricanAmerican-vs-Asian |
1.883450E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
5.88080000000213E-05 |
Normal-vs-Female |
1.66831999999228E-05 |
Male-vs-Female |
2.707000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
2.194100E-02 |
Normal-vs-Extreme_Weight |
1.153940E-04 |
Normal-vs-Obese |
4.935800E-03 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
3.567800E-01 |
Normal_Weight-vs-Obese |
9.521800E-02 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
2.268800E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
1.64437999999878E-05 |
Normal-vs-Age(41-60Yrs) |
2.440100E-03 |
Normal-vs-Age(61-80Yrs) |
1.77246999999436E-05 |
Normal-vs-Age(81-100Yrs) |
2.627600E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.562600E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.445600E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.413600E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.771600E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.207400E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.953800E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
9.573400E-01 |
Normal-vs-Grade 3 |
7.215200E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
6.015800E-01 |
Grade 2-vs-Grade 4 |
9.573400E-01 |
Grade 3-vs-Grade 4 |
7.215200E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
1.59789999999438E-05 |
Normal-vs-N1 |
1.094410E-02 |
N0-vs-N1 |
5.039600E-01 |
|
|